The dual-listing is a liquidity-enhancing move but does not change fundamentals or raise capital. Monitor for increased trading volumes and potential index inclusion in Israeli benchmarks, but no immediate catalyst for the stock price on Nasdaq. The company remains pre-commercialization with no approved product, so focus should remain on clinical trial milestones and regulatory progress.
Price Chart
Executive Summary
Alpha Tau Medical announced its intention to dual-list its ordinary shares on the Tel Aviv Stock Exchange (TASE) while maintaining its Nasdaq listing. The company registered all outstanding shares (92,478,154) plus potential future issuances from warrants, options, RSUs, and employee plans for TASE trading. This listing broadens the shareholder base and provides Israeli investors access in local currency and hours, but does not involve raising new capital or changing the Nasdaq status.
Key Facts
- Alpha Tau intends to dual-list on Tel Aviv Stock Exchange (TASE) alongside existing Nasdaq listing.
- Registered shares include 92,478,154 outstanding ordinary shares; up to 36,733,096 shares underlying existing convertible securities (warrants, options, RSUs); up to 12,889,753 from authorized but unissued options; and up to 4,257,358 from the employee share purchase plan.
- No new capital raising or change in Nasdaq listing status involved.
- Shares will trade on TASE under symbol DRTS (English) and a Hebrew symbol.
- Alpha DaRT treatment is not yet approved for commercial use outside clinical trials.
Financial Impact
No financial figures disclosed; dual-listing does not involve new capital raise or immediate dilution.
Risk Factors
- Dual-listing does not address the lack of approved commercial product or potential clinical trial setbacks.
- Potential for increased administrative costs and regulatory compliance burden from operating on two exchanges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-086947 |
| Document: ea030130901ex99-1.htm | 0001213900-26-086947 |
| Document: 0001213900-26-086947-index-headers.html | 0001213900-26-086947 |
| Document: 0001213900-26-086947-index.html | 0001213900-26-086947 |
| Document: 0001213900-26-086947.txt | 0001213900-26-086947 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 6-K | $14.11 $15.19 | ▲ +7.65% | ▲ +7.84% | $14.77 (+4.68%) |
Aug 10, 2026 7w ago | 6-K | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | Press Release | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | 6-K | $13.60 $14.84 | ▲ +9.12% | ▲ +10.03% | $14.77 (+8.60%) |
Jul 21, 2026 10w ago | 6-K | $13.32 $14.26 | ▲ +7.06% | ▲ +4.50% | $14.77 (+10.89%) |
Jul 15, 2026 11w ago | 6-K | $12.46 $13.87 | ▲ +11.32% | ▲ +8.97% | $14.77 (+18.54%) |
Jun 23, 2026 14w ago | 6-K | $10.05 $13.01 | ▲ +29.45% | ▲ +27.52% | $14.77 (+46.97%) |
Jun 3, 2026 17w ago | Press Release | $10.58 $13.23 | ▲ +25.05% | ▲ +26.05% | $14.77 (+39.60%) |
May 11, 2026 20w ago | Press Release | $10.34 $9.19 | ▼ −11.12% | ▼ −10.82% | $14.77 (+42.84%) |
May 8, 2026 21w ago | Press Release | $8.51 $9.35 | ▲ +9.87% | ▲ +9.85% | $14.77 (+73.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access